Drug firm Laurus Labs Ltd on Thursday (October 23) has provided its outlook for FY 2026, projecting continued strength in business momentum seen during the first half of the year.

The company expects revenue growth to be driven by a robust Contract Development and Manufacturing Organisation (CDMO) industry outlook, along with sustained clinical and commercial business momentum and the ramp-up of growth projects.

The generics segment is also expected to post growth, supported by Contract Manufacturing Organisation (CMO) opportunities and a stable antiretroviral (ARV) business.

On the profitability front, Laurus Labs anticipates underlying EBITDA margins to be higher in FY 2026, aided by better asset utilisation, an improved product mix, and a continued focus on operational excellence.

See Full Page